Activating BRAF mutations that deregulate the mitogen-activated protein kinase (MAPK) pathway commonly occur in cancer. BRAF V600E induces centrosome amplification and spindle abnormalities that result in aneuploidy. We find modification of Mps1 is critical for contributing to centrosome amplification and chromosome instability induced by BRAF V600E . Phosphorylation of Mps1 at residue S281 induced by BRAF V600E stabilizes Mps1 protein by preventing its ubiquitination by APC/C and subsequent degradation, allowing the non-degraded protein to accumulate at centrosomes. Cells in which endogenous Mps1 was replaced with a phospho-mimetic Mps1 mutant are viable but amplify centrosomes and missegregate chromosomes frequently. Importantly, analysis of tumor micro arrays revealed that phospho-MAPK and S281-phosphorylated Mps1 were highly correlated in human melanoma tissues, implying that MAPK contributes to defects in the degradation of Mps1 in situ. We propose that continuously activated BRAF V600E signaling may be a possible mechanism for the deregulation of Mps1 stability and kinase activity in human tumors, and that persistent phosphorylation of Mps1 through BRAF V600E signaling is a key event in disrupting the control of centrosome duplication and chromosome stability that may contribute to tumorigenesis. Our findings raise the possibility that targeting the oncogenic BRAF and S281-phosphorylated Mps1, especially when used in combination could potentially provide great therapeutic opportunities for cancer treatment.
INTRODUCTION
The RAF-MEK-MAPK signaling is a central pathway that regulates cell growth, proliferation, differentiation and survival in response to extracellular stimuli and has an important role in human cancer. 1 A link between mutations activating the mitogenactivated protein kinase (MAPK) pathway and cancer development was provided by genetically engineered mouse models. Cells isolated from these mice display activation of the MAPK pathway and are partially transformed. 2 Somatic mutations in BRAF have been found in B6% of human cancer, with the highest incidence in malignant melanoma (B70%). 3 More than 90% of the oncogenic BRAF mutations occur as V600E. It has been shown that V600E causes a 500-fold activation of BRAF, and BRAF V600E can stimulate constitutive MEK-MAPK signaling in cells and induce melanoma in mice, 4 showing that it can be a founder mutation in melanoma. Importantly, BRAF V600E inhibition blocks melanoma cell proliferation, induces apoptosis in vitro and blocks melanoma xenograft growth in vivo. 5 These data validate BRAF V600E as a driver of melanomagenesis and as a therapeutic target in melanoma, 6 ,7 yet the mechanism through which BRAF V600E exerts its transforming properties remains poorly understood. Most human tumors exhibit abnormal chromosome numbers, known as aneuploidy, which may be a driving force for cellular transformation. 8 Previous studies from our laboratory show that BRAF V600E causes excess centrosomes and may be a key contributor to aneuploidy in melanoma. 9 It is, however, unclear how BRAF V600E leads to aneuploidy.
Aneuploidy primarily results from chromosome segregation errors that can arise due to faulty spindle checkpoint control or centrosome amplification. 10 In this study, we focus on the impact of centrosome amplification on the integrity of the genome. Excess centrosomes are found in many human tumors and promote the assembly of abnormal spindles in situ. In some tumors, extra centrosomes are apparent before the appearance of aneuploidy. 11 Accordingly, these observations suggest that defects in the control of centrosome duplication might promote genetic instability, which has been proposed to be an important early event in tumorigenesis. 12 The Mps1 protein kinase has been implicated in the control or centrosome number. The role of Mps1 at centrosomes is contentious, 13 --17 and if accepted at face value recent inhibitor studies show that Mps1 is not required for centrosome duplication.
18 --20 However, not being required is not the same as having no role. The presence of active Mps1 has been documented at centrosomes, 21 several groups have shown that wild-type Mps1 can accelerate centrosome re-duplication in tumor-derived cells, 13,16,22 --25 and defects in Mps1 degradation have been shown to cause centrosome re-duplication; overexpression of cyclin A, which promotes phosphorylation of Mps1 at T468, mutations in Mps1 that mimic T468 phosphorylation or remove a degradation signal, or suppression of antizyme, each prevent the antizyme-mediated degradation of Mps1 specifically at centrosomes, elevating centrosomal Mps1 levels and causing centrosome re-duplication, 15, 23, 26 whereas mutating the Mps1 D-box prevents anaphase promoting complex/cyclosome (APC/C)-dependent degradation and also causes centrosome amplification. 25 Accordingly, regardless of whether Mps1 is required for centrosome duplication, increasing its levels at centrosomes causes centrosome re-duplication as verified here.
The aim of this study is to better understand the mechanism of how BRAF V600E causes centrosome amplification and spindle abnormalities, and thereby to provide a molecular basis for the link between the BRAF V600E signaling-induced centrosome amplification and genomic instability in human melanoma cells. On the basis of our findings, we propose that phosphorylation of Mps1 at residue S281 by BRAF V600E signaling prevents the ubiquitination of Mps1 by the APC/C and its subsequent degradation, thus allowing the Mps1 protein to accumulate in excess at centrosomes. An Mps1 mutant that mimics phosphorylation at S281 is sufficient to trigger centrosome amplification, leading to chromosome instability in human melanoma cells. Furthermore, this study also validates the association between the activities of BRAF V600E signaling and Mps1 protein level in human melanoma tissues by means of tissue microarrays (TMAs). Phospho-MAPK and phosphoMps1 (S281) immunoreactivities were correlated, and both significantly increased from normal skin to primary malignant and metastasic melanoma, suggesting a correlation between the MAPK and S281-phosphorylated Mps1 protein level in human melanoma tissues. Our findings provide a molecular linkage between BRAF V600E pathway and Mps1 kinase, and suggest that deregulation of Mps1 modification by BRAF V600E signaling has an important role in human melanoma.
RESULTS

Mps1 is critical for BRAF
V600E -induced centrosome amplification and multipolar spindle formation To test whether Mps1 is a critical target of BRAF V600E mutant that contributes to centrosome amplification and aberrant spindle structures observed in melanoma cells, an RNAi approach was used to silence endogenous Mps1. BRAF V600E -expressing Sbcl2 or SK-MEL31 cells were infected with pSUPER-Mps1 retrovirus, which achieved a more than 90% reduction in Mps1 levels (Supplementary Figure S1A -B and Supplementary Figure S2A-B) . At 120 h post-infection, cells were fixed and subjected to immunofluorescence (IF) with anti-a-and anti-g-tubulin antibodies. Roughly 70% of the BRAF V600E -expressing mitotic cells displayed visible aberrant spindle structure with either multiple spindle poles (36%) or disorganized microtubules (32%), which is consistent with failures in spindle formation as described previously. 9 Interestingly, only 6% of BRAF V600E -expressing Sbcl2 and SK-MEL31 cells displayed multipolar spindles when Mps1 was depleted, while there was no change in cells with disorganized microtubules (Supplementary Figure S1C and Figure S2C ). Furthermore, the percentage of BRAF V600E -expressing cells with three or more centrosomes was reduced from 30 to 6% when Mps1 was absent (Supplementary Figure S1D and Figure S2D ). BRAF V600E also caused Mps1-dependent centrosome re-duplication in an HU-arrest assay (Supplementary Figure S1F) . Together, this demonstrates that BRAF V600E signaling causes centrosome amplification and multipolar spindles at least in part through Mps1-dependent defects in centrosome duplication, although there may be other targets for BRAF V600E that lead to disorganized spindles with p2 centrosomes, which remains to be addressed in the future.
BRAF
V600E increases Mps1 protein level by stabilization, allowing the accumulation of excess Mps1 at centrosomes Mps1 is degraded through the APC/C-mediated ubiquitin --proteasome pathway. 25 To test the effect of BRAF V600E signaling on the ubiquitination of Mps1, in vivo ubiquitin analysis was performed in synchronized control and BRAF V600E -expressing 293T cells. The level of ubiquitin --Mps1 complex was significantly reduced in BRAF V600E -expressing cells (Figure 1a) . To assess the consequences of this reduced ubiquitination, Sbcl2 control and BRAF
V600E
-expressing cells were incubated with nocodazole overnight, released into fresh medium, and collected at different times for western blot. As expected, Mps1 protein was quickly degraded within half an hour in control cells (Figure 1b left panel) . However, the expression of BRAF V600E results in Mps1 protein stabilization (Figure 1b right 15 We found that BRAF V600E increased the levels of Mps1 at centrosomes by approximately fivefold, compared with control cells (Figures 1c and e) . Furthermore, although in control cells the Mps1 signal was completely lost during anaphase, a strong Mps1 signal around the pole and the spindle area in BRAF
-expressing anaphase cells (Figure 1d ), indicating that Mps1 degradation was delayed during anaphase. Together, these results strongly suggest that BRAF V600E stabilized the Mps1 protein during mitotic exit, allowing the non-degraded Mps1 to accumulate in excess at centrosomes during the subsequent interphase.
Identification of BRAF V600E signaling-dependent phosphorylation sites on human Mps1 by LC-MS/MS analysis Human Mps1 contains nine T/SP motifs that are potentially targeted sites for phosphorylation by a proline-directed kinase, such as CDKs and MAPKs. As our previous data indicated a role of BRAF V600E in Mps1 stabilization and phosphorylation, 27 we sought to further identify the BRAF V600E signaling-dependent phosphorylation sites within human Mps1 in the presence or absence of MEK inhibitor, U0126. GST-BRAF V600E was co-transfected with green fluorescent protein (GFP)-Mps1 wild type into 293T cells. Similar levels of BRAF V600E were expressed in the transfectants (Supplementary Figure S3A) . The lysates prepared from the transfectants were subjected to immunoprecipitation with anti-GFP antibody and silver staining (Supplementary Figure S3B) . Multiple electrospray ionization-liquid chromatography/tandem mass spectrometry runs were carried out to identify the phosphopeptides. With around 60% coverage of Mps1 from three independent runs, we were able to identify four serines or threonines that were phosphorylated (Supplementary Figure S3C) . Three phospho-residues, S281, S436, and S821, each followed by a proline, were phosphorylated in the absence of U0126 and dephosphorylated in the presence of U0126, suggesting that their phosphorylation is mediated by BRAF V600E through MAPK. The BRAF V600E signaling-dependent phosphorylated sites are highly conserved among all vertebrate Mps1 proteins (Supplementary Figure S3D) . Further immunoblotting analysis of the phosphorylation-defective Mps1 mutants (S281A, S436A, S821A, and AAA) on a long 6% gel shows that the U0126-treated Mps1-WT sample and Mps1-AAA migrate similarly (Supplementary Figure S3E) , indicating that the observed mobility shift is due to MAPK-dependent phosphorylation at S281, S436, and S821. We previously reported the phosphorylation of S821 was targeted by MAPK and required for Mps1 recruitment to the kinetochores. In this report, we focus on BRAF V600E signaling-dependent phosphorylation sites at S281 and S436.
Phosphorylation of S281 attenuates the degradation of Mps1 through the APC/C Cdc20 pathway
To understand how BRAF V600E signaling regulates Mps1 stability, point mutations of the phosphorylation sites were made in the pBabe-puro-HA-Mps1 expression vector (Supplementary Figure  S3F) , and the mutant proteins were tested for their stability in Sbcl2 cells. Sbcl2 cells were infected with pBabe-HA-Mps1-WT or mutant plasmids. Forty-eight hours post infection, cells were incubated overnight in the presence of nocodazole (40 ng/ml), released into fresh medium, then collected at different times and subjected to western blot by using anti-HA antibody. As expected, Mps1-WT protein was quickly degraded within half an hour. It is also clear that the mutation of the putative D-box prevents Mps1 degradation. Interestingly, mutation of S281 to glutamic acid results in stabilization of the Mps1 protein ( Figure 2a , lanes 3), whereas the other mutants have no significant effect on degradation, indicating that S281 is responsible for Mps1 stability.
Next, we sought to evaluate the possibility that S281 phosphorylation suppresses APC/C-mediated degradation by examining Mps1 levels in cells overexpressing Cdc20. 293T cells were transiently co-transfected with pEF36-HA-Mps1-WT or mutants and different concentrations of hFlag-Cdc20 expression vectors. Cells were lysed after 48 h of incubation and evaluated for Mps1 protein levels by western blot. Mps1-WT protein was significantly decreased when Cdc20 was overexpressed. Similarly, Cdc20 upregulation results in a decrease in the levels of Mps1 S436 and S821 mutants. However, the levels of Mps1 S281E did not change when Cdc20 was overexpressed ( Figure 2b right panel 2nd set of lanes); suggesting that phosphorylation of S281 attenuates Mps1 degradation by the APC/C Cdc20 pathway. (a) Stability of wild-type versus mutated Mps1. Sbcl2 cells were infected with pBabe-HA-Mps1-WT or mutant plasmids. Forty-eight hours post infection, cells were incubated overnight in the presence of nocodazole (40 ng/ml), released into fresh medium, then collected at different times and subjected to western blot by using anti-HA antibody. (b) 293T cells were transiently co-transfected with pEF36-HA-Mps1-WT or mutants and different concentrations of hFlag-Cdc20 expression vectors. Mock transfections were also pursued with empty vector. Cells were lysed after 48 h of incubation and evaluated for Mps1 protein levels by western blot analysis with anti-HA antibody. The western blot was also probed with anti-Flag antibody to detect Cdc20 expression. (c) HA-Mps1-WT-and mutant-expressing Sbcl2 cells were treated with MG115 (25 mM). Cell lysates were subjected to immunoprecipitation (IP) with equal amounts of control mouse IgG or anti-HA antibody and resolved by SDS --PAGE. The immunoprecipitates were subjected to western blotting with anti-Cdc27 antibody. The reverse experiment was also shown as the bottom panel using anti-Cdc27 antibody IP and anti-HA antibody western blotting. (d) 293T cells were co-transfected with pHF36-HAMps1 mutants and His6-ubiquitin plasmids and incubated for 24 h. The proteasome inhibitor, MG115 (25 mM), was added 6 h before lysis. Onefifth of the cell lysates were subjected to western blotting for expression level of Mps1 protein (the bottom panel) and four-fifth of the cell lysates were subjected to ubiquitination analysis (ubiquitination complexes, the upper panel). His-Ub pulled out over nickel columns and then blotted with anti-HA antibody. The panel at right shows the initial exposure (2 min exposure), whereas the panel at left was overexposed (5 min) to reveal ubiquitination of the S281E and DD-box mutants.
Phosphorylation of S281 abolishes the binding of Mps1 to Cdc27, thus diminishing Mps1 polyubiquitination To further evaluate whether phosphorylation of S281 affects the APC/C-dependent degradation of Mps1, we examined the interaction of Mps1 with Cdc27 (an integral subunit of APC/C). To do this, we overexpressed wild-type and mutated HA-Mps1 in Sbcl2 cells, and subjected protein extracts to immunoprecipitation with anti-HA (or anti-Cdc27) antibody and western blot with antiCdc27 (or anti-HA) antibody. Cdc27 was readily detected in Mps1 immunoprecipitates from cells expressing wild-type, S436, or S821 mutant Mps1, indicating that mutations of S436 and S821 did not compromise the binding of Mps1 to Cdc27. The only mutant that lost the ability to bind Cdc27 was S281E (Figure 2c the top panel) . Likewise, HA-Mps1 protein was hardly detected in Cdc27 immunoprecipitates from Mps1 S281E-expressing cells (Figure 2c the bottom panel). Hence, these data indicated that phosphorylation of Mps1 at S281 abolished its ability to bind Cdc27.
Furthermore, we examined whether phosphorylation of S281 affects the ubiquitination level of Mps1 protein. The first lane in both left and right panel in Figure 2d shows an accumulation of polyubiquitinated wild-type Mps1. Similar results were obtained when cells were transfected with S281A, S436A/E, and S821A/E. However, the ability of S281E to bind ubiquitin was significantly compromised, suggesting that phosphorylation of S281 prevents polyubiquitination of Mps1. It is important to note that the panel at right shows the initial exposure (2 min exposure), although it required a 5-min exposure of the blot (left panel) to reveal ubiquitination of the S281E and DD-box mutants.
Phosphorylation of S281 allows accumulation of excess Mps1 at centrosomes We further determined whether phosphorylation of S281 regulates the accumulation of Mps1 at centrosomes. Using the standardized imaging protocol described in Materials and methods, we determined the normalized GFP and g-tubulin signals from 12 cells, limiting our analysis to cells with one centrosome. In some experiments, a 4-h MG115 treatment was used to prevent protein degradation. Using this protocol we cannot effectively distinguish between signals that are exclusively centrosomal and those found in pericentrosomal regions adjacent to the centrosome. Thus, in these experiments we refer to the accumulation of Mps1 in the vicinity of centrosomes. As shown in Supplementary Figure S4 , the Mps1 signal in the vicinity of centrosomes in cells expressing GFP-S436E or GFP-S821A/E was similar to that seen in cells expressing wild-type Mps1. In contrast, GFP-S281A could not efficiently accumulate at centrosomes. However, GFP-S281A could accumulate in the vicinity of centrosomes after a 4-h treatment with MG115. Interestingly, the GFP signal in the vicinity of centrosomes was markedly stronger in cells-expressing S281E. Together, these observations suggest that phosphorylation of S281 suppresses Mps1 degradation thereby increasing the ability of Mps1 to accumulate at centrosomes and/ or peri-centrosomal regions. S436A also abolished this accumulation of Mps1 (Supplementary Figures S4A, 5th panel, and D) , indicating that phosphorylation of S436 is also required for the accumulation of Mps1 at or near centrosomes.
Phospho-mimetic Mps1 is sufficient to trigger centrosome duplication defects in 293T cells To further detect the effects of phospho-mimetic Mps1 mutants on the centrosome duplication and spindle formation, we depleted the endogenous Mps1 from 293T cells using pSUPERMps1 as described previously and compared centrosome number and spindle formation in cells ectopically expressing wild-type, phospho-mimetic (S281E, S436E, S821E, and EEE) or phosphodefective (AAA) Mps1 mutants. As expected, immunofluorescence staining of g-tubulin and a-tubulin revealed that overexpression of Mps1-WT is not sufficient to cause centrosome amplification and formation of multipolar spindles in 293T cells, which is consistent with previous reports from our group and others. 17, 23, 25 Similar results were obtained in cells-expressing either the S821E or AAA mutant proteins. In contrast, supernumerary centrosomes and multipolar spindles were observed in S281E-and S436E-expressing cells (Figures 3a and b) , indicating that mutations that mimic phosphorylation of Mps1 at S281 or S436 are sufficient to trigger centrosome amplification and multipolar spindles. Importantly, the EEE mutant has much more severe effects on centrosome amplification as compared with either S281E or S436E alone, indicating that phosphorylation at both residues, as is actually observed in BRAF V600E -expressing cells, is critical for the generation of mitotic abnormalities. To determine whether the observed centrosome amplification could be due to a defect in centrosome duplication, we transfected S-phase arrested cells with the various Mps1 constructs, and assessed whether Mps1 mutants led to centrosome re-duplication. As shown in Figure 3d , centrosome number was similar to controls in wild type-, S821E-, and AAAexpressing cells. However, excess centrosomes were observed in roughly 55, 30, or 70% of S281E-, 436E-, and EEE-expressing cells, respectively. This explicitly demonstrates that mimicking phosphorylation of Mps1 at S281 and/or S436E causes centrosome re-duplication, and suggests that the centrosome amplification observed in Figures 3a and b occurs through a defect in centrosome duplication.
S436 phosphorylation regulates the kinase activity of Mps1
Because phosphorylation has been show to be an important activation mechanism for many protein kinases, including Mps1, 21 ,22,28 we tested whether the phosphorylation of Mps1 at S281, S436, and S821 affects Mps1 kinase activity. For comparison, a kinase-dead (KD) was used as a control. As expected, Mps1-WT phosphorylated MBP efficiently, whereas Mps1-KD was inactive. Mps1 S281E and S821E have kinase activity comparable to wild type. However, whereas S281A and S821A cause only modest reductions in kinase activity, S436A kinase activity was noticeably reduced, suggesting that phosphorylation of S436 is important for the kinase activity of Mps1 in vitro. Moreover, S436E and EEE mutants have higher kinase activity as compared with Mps1-WT (Supplementary Figure S5) .
Phospho-mimetic Mps1 (EEE) induces chromosome mis-segregation in human melanoma cells
To determine whether the amplified centrosomes and the resultant spindle abnormalities induced by phospho-mimetic mutation of Mps1 give rise to chromosome segregation errors, we examined later stages of mitosis in Sbcl2 cells stably expressing pBabe-puro-Mps1-EEE mutant. For the primary human melanocytes, cells were infected with pBabe-puro-Mps1-EEE mutant retrovirus, which achieved more than 90% infection efficiency as monitored by GFP fluorescence of a transfected GFPcontaining plasmid. Ninety-six hours post infection, cells were subjected to metaphase-spreads analysis. In contrast to vector control cells, expression of the Mps1-EEE mutant in either Sbcl2 or primary human melanocytes resulted in a high frequency of chromosome segregation anomalies, with the predominant phenotype being multipolar spindle phenotype, although a few cells showed the lagging-chromosomes phenotype despite having assembled apparently bipolar spindles (Figures 4a and b and Supplementary Figure S6A) . It stands to reason that the high incidence of defective mitosis observed in the Mps1-EEE-expressing cells would result in aneuploidy. To test for this directly, chromosome counts on metaphase spreads were done from vector control or Mps1-EEE mutant-expressing Sbcl2 or primary human melanocytes. A mode of 46 chromosomes was observed for vector control cells, indicating that most of the cells in culture are diploid. In contrast, ectopic expression of the Mps1-EEE mutant resulted in the absence of a chromosome mode and a wider distribution of chromosome counts (Figures 4c and d and Supplementary Figure S6B ). Taken together, we conclude that phospho-mimetic mutation of Mps1 (EEE) induces aneuploidy in human melanoma cells.
Oncogenic BRAF attenuates the ability of antizyme to remove Mps1 from centrosomes The observation that MG115 treatment restores the ability of Mps1-S281A to accumulate at centrosomes and peri-centrosomal regions suggests that phosphorylation of Mps1 at S281 is not required for centrosomal targeting per se, but rather for the ability of Mps1 to accumulate at centrosomes. Antizyme (OAZ) was reported to restrain centrosome amplification by regulating the accumulation of Mps1 at centrosomes. 15 To determine whether oncogenic BRAF affects OAZ, we tested the OAZ protein level in pBabe control and pBabe-BRAF V600E -expressing cells. As shown in Figure 5 , BRAF V600E expression does not affect either the whole cell (Figure 5a ) or centrosomal (Figure 5b ) levels of the OAZ protein. To test whether oncogenic BRAF renders Mps1 insensitive to OAZ, we transfected OAZ plasmids into Mps1-WT or EEE mutant-expressing SK-MEL31 cells. We found that overexpression of OAZ led to the loss of Mps1-WT from centrosomes. However, the OAZ overexpression did not lead to any dramatic change in centrosomal Mps1-EEE mutant, indicating that phospho-mimetic Mps1-EEE mutant is insensitive to OAZ (Figure 5c ). To further confirm this, we performed OAZ depletion to downregulate physiological antizyme activity and then examined the accumulation of Mps1 mutants in the vicinity of centrosomes. As shown in Figure 5d , the phospho-mimetic (EEE), which is resistant to OAZ overexpression, localizes to centrosomes in cells transfected with either control scrambled siRNA control or OAZ-specific siRNA. Moreover, depletion of antizyme restores centrosomal accumulation of phospho-defective (AAA) Mps1. Collectively, this data suggests that BRAF V600E has no direct effect on antizyme, but rather that the resulting phosphorylation of Mps1 renders centrosomal Mps1 insensitive to antizyme-mediated degradation.
Phosphorylation of Mps1 at residue 281 is associated with the activity of BRAF V600E signaling in human melanoma tumors
The observed findings in vitro pressed us to investigate the relevance of the inhibition of Mps1 protein degradation by BRAF V600E signaling in situ. We evaluated the correlation between the level of S281-phosphorylated Mps1 and the activity of BRAF V600E signaling by immunohistochemistry using a tissue microarray of clinical samples from 69 cases/207 cores (ME207). We raised anti-rabbit polyclonal anti-S281 Mps1 antibody to detect the BRAF V600E -sepecific phosphorylation of Mps1 and its level in situ. Analysis of this tissue array revealed that the percentage of p-MAPK positive cases (positive plus strong positive) significantly increased from normal skin (0%) to malignant melanomas (48%) and malignant metastases (69%; Po0.001; Figure 6c left panel) . Similarly, p-S281 Mps1 immunoreactivity significantly increased from normal skin (0%) to malignant melanomas (54%) and malignant metastases (91%; Po0.001; Figure 6c right panel) . Furthermore, we found that the samples showing strong p-MAPK staining also showed strong p-S281 Mps1 staining, whereas samples with weak p-MAPK staining showed weak p-S281 Mps1 staining, suggesting that p-S281 Mps1 staining positively correlated with p-MAPK in human melanoma tissues (r ¼ 0.25, P ¼ 0.002, Spearman test).
DISCUSSION
In this study, we describe a possible mechanism by which oncogenic BRAF causes centrosome re-duplication and aneuploidy and correlates with tumorigenesis in vivo (Supplementary Figure S7) . BRAF V600E signaling leads to phosphorylation of Mps1 at S281, abolishing the binding of the APC/C to Mps1, and Figure 4 . Mps1-EEE drives mis-segregation of chromosomes and aneuploidy in human melanoma cells. Sbcl2 cells or primary human melanocytes were infected with pBabe-puro-HA-Mps1-EEE retrovirus. Sbcl2 cells infected with pBabe-puro-Mps1-EEE mutant or empty vector retrovirus were selected under puromycin (1 mg/ml) for 10 days and subjected to metaphase spreads. The primary human melanocytes were infected with pBabe-puro-Mps1-EEE mutant or empty vector retrovirus. The efficiency was B90% as monitored by GFP fluorescence of a transfected GFP-containing plasmid. Ninety-six hours post infections, cells were subjected to metaphase spreads analysis. attenuating Mps1 polyubiquitination. Our data predict that BRAF V600E signaling would also phosphorylate Mps1 at S436, and that S436E has higher kinase activity. The failure to properly degrade Mps1 leads to the accumulation of excess Mps1 with high kinase activity in the vicinity of centrosomes, resulting in centrosome amplification, multipolar spindles, and chromosome mis-segregation, which are potential mechanisms for aneuploidy and chromosome instability in cancer. Furthermore, these findings were confirmed in situ. p-S281 Mps1 not only stained positive but also correlated significantly with p-MAPK in human malignant melanoma (MM) and metastatic MM; this study implies a role of persistent phosphorylation of Mps1 through BRAF V600E signaling in human melanoma tumorigenesis.
The Mps1 kinase has been suggested to be involved in centrosome duplication, 13 --16 although it has been controversial. 17 However, regardless of whether Mps1 is required for centrosome duplication, active Mps1 is found at centrosomes, 21 overexpression of Mps1 can accelerate centrosome re-duplication, 22 --25 and preventing the degradation of Mps1 at centrosomes causes centrosome re-duplication. 15, 23, 26 This study from our laboratory verifies the conclusion that increasing the centrosomal levels of Mps1 causes centrosome re-duplication. Furthermore, our study reveals that BRAF V600E cannot generate supernumerary centrosomes and multipolar spindles in Mps1-depleted cells, although it is able to cause disorganized spindles (Supplementary Figure S1) , indicating that BRAF V600E -expressing cells do not undergo centrosome amplification in the absence of Mps1. Mps1 is also known to be involved in the spindle checkpoint, defects in which can also generate centrosome amplification by causing cytokinesis failures. 16 It is important to note that we have used S-phase arrest assays to explicitly show that BRAF V600E signaling can cause centrosome re-duplication, which is unambiguously a defect in the control of centrosome duplication (Supplementary Figure S1F) . Moreover, this BRAF V600E -dependent centrosome re-duplication is attenuated by Mps1 depletion, suggesting that BRAF V600E signaling promotes the production of supernumerary centrosomes and resultant multipolar spindles in human melanoma cells via the centrosome re-duplication function of Mps1.
Our previously published paper reports that BRAF V600E signaling prolongs activation of the spindle checkpoint and delays mitotic exit in an Mps1-dependent manner. 27 In this manuscript, we observe that nocodazole-release activates APC/C, leading to Mps1 degradation in control cells. However, the Mps1 protein shows resistance to APC/C upon release of BRAF V600E -expressing cells from nocodazole (Figure 1b ). Mps1 is a protein kinase whose activity is essential for spindle-checkpoint signaling. Mps1 is degraded after the metaphase-to-anaphase transition, so that as cells enter anaphase, Mps1 levels fall, and the spindle checkpoint is turned off. However, in budding yeast, all the components of this pathway downstream of Mps1 are functional in anaphase and the spindle checkpoint can be reactivated in anaphase by overexpressing Mps1. 29 So, it is possible that by phosphorylating Mps1 and preventing its degradation, BRAF V600E reactivates the spindle-assembly checkpoint in anaphase and causes an Mps1-dependent delay in anaphase/telophase exit rather than a delay at metaphase. Further experiments will need to be done to elucidate the precise mechanism for the mitotic delay caused by BRAF V600E . Mps1 is hyperphosphorylated during mitosis and phosphorylation could be a compelling mechanism to regulate Mps1 function. 21, 22, 30 We propose that BRAF V600E signaling deregulates Mps1 stability through phosphorylation, and this hypothesis is supported by the data in Supplementary Figure S3A , which shows that BRAF V600E signaling causes hyperphosphorylation of Mps1 in 293T cells. MAPK has been shown to be important for Mps1 kinetochore localization in Xenopus, 31 however, there are no known regulatory subunits or upstream activating kinases for Mps1. This study identifies a new upstream activating kinase for Mps1. Furthermore, the liquid chromatography-mass spectrometry (LC-MS/MS) spectra identify three BRAF V600E -dependent phosphorylation sites within Mps1 (Supplementary Figure S3C) . Phosphorylation of endogenous Mps1 at S281, S436, and S821 from mitotic extracts has been previously reported, 28 and S436 phosphorylation has been shown in vitro previously by Cdk2. 23 Our biochemical and cellular data suggest that hyperphosphorylation of Mps1 at S281 by BRAF V600E signaling is one mechanism that deregulates Mps1 degradation in human melanoma cells. Phosphorylation at S281 abolishes the ability of Mps1 to interact with Cdc27 and also significantly attenuates the ubiquitination of Mps1 (Figure 2 ). On the basis of our data so far, we hypothesize that S281E is unable to bind Cdc27 and, therefore, cannot be delivered to the APC/C ligase for ubiquitination and consequent degradation, allowing increasing amounts of Mps1 protein.
Increasing Mps1 level is sufficient to cause centrosome re-duplication in human cells. 15,21 --26,32 This study further confirmed that the failure to degrade Mps1, in this case due to phosphorylation at S281, is sufficient to induce centrosome amplification and aberrant spindles, and an HU-arrest assay demonstrated that S281E and EEE mutants specifically promote centrosome re-duplication in 293T and SK-MEL31 cells (Figure 3 ). Our observations have led to the hypothesis that centrosome amplification in BRAF V600E -expressing cells is the result of centrosome re-duplication as a consequence of the attenuation of Mps1 degradation by BRAF V600E signaling. Ideally, we should deplete endogenous Mps1 in selected cell lines and re-express a non-targetable Mps1 S281A mutant to prove this model. Unfortunately, although adding MG115 bypassed the need for the modification of Mps1 to prevent degradation, the MG115 experiment would not be expected to have an effect on centrosomes re-duplication based on previous papers showing that the proteasome is required for re-duplication. 33 --37 The observation that preventing Mps1 degradation at centrosomes causes centrosome re-duplication in human cells suggests that Mps1 might contribute to the excess centrosomes seen in human tumors. Thus, Mps1 potentially represents a link between the control of centrosome duplication and the loss of genomic integrity in human cancer. 24 Few chromosome segregation errors were observed in Sbcl2 and primary human melanocytes. However, expression of Mps1-EEE enhanced the frequency and severity of chromosome segregation errors without causing cell death. Moreover, the phospho-mimetic Mps1-EEE mutant is sufficient to rapidly induce aneuploidy in human melanoma cell lines (Figure 4) . Recently, antizyme was shown to localize to centrosomes and modulate centrosome overproduction. 38 Antizyme restrains centrosome amplification by regulating the accumulation of Mps1 at centrosomes. 15 Our results rule out a role of oncogenic BRAF on the accumulation of antizyme at centrosomes (Figures 5a and b) . However, the Mps1-EEE mutant is insensitive to antizyme, suggesting that the BRAF-dependent phosphorylation attenuated the ability of antizyme to remove Mps1 from centrosomes (Figures 5c and d) . The fact that MG115 treatment restores recruitment of S281A to the centrosome indicates that phosphorylation at this site is not required for targeting to centrosomes. Rather, phosphorylation of S281 increases the ability of Mps1 to accumulate at centrosomes (Supplementary Figure S4) . One possibility is that wild type Mps1 or some mutants (S436E, S821A/E) are rapidly removed from centrosomes by antizyme-mediated degradation. However, mimicking phosphorylation at S281 site suppresses this antizymemediated degradation event thereby increasing the level of Mps1 at centrosomes. Together, it seems more likely that BRAF V600E signaling is modulating the accumulation of Mps1 at centrosomes by preventing antizyme-mediated degradation of Mps1.
Finally, to test the correlation of BRAF V600E signaling with the regulation of Mps1 degradation in situ, we generated antiphospho-S281 Mps1 polyclonal antibody and performed TMAs. Consistent with our in vitro data, we found a significant difference in the expression p-S281 Mps1/p-MAPK between normal skin, malignant melanoma (MM) and MM metastases ( Figure 6 ). Among the MM metastases, 91% showed positive p-S281 Mps1 staining and 69% showed positive p-MAPK staining. The corresponding percentages for the primary malignant melanoma were 54% (p-S281 Mps1) and 48% (p-MAPK). In normal skin tissues, 100% of samples showed no p-S281 Mps1 or p-MAPK staining. p-S281 Mps1/p-MAPK were clearly more abundantly expressed in MM metastases than in MM and normal skin. Notably, p-S281 Mps1 positivity was correlated with MAPK activity. Metastasis is a major cause of cancer-related mortality. The fact that patients with higher MAPK activity in melanoma tissues show higher expression of p-S281 Mps1 and more metastases supports a role for BRAF V600E signaling-dependent regulation of Mps1 function in the motility and aggressiveness of human melanoma. Further functional assays are required to determine the exact role of Mps1 and BRAF V600E signaling in these biological processes in situ. In conclusion, on the basis of our findings in human melanoma cells and tissues, we propose that modification of Mps1 is crucial for BRAF V600E signaling and has an important role in genomic instability (Supplementary Figure S7) . These data highlight that continuously activated BRAF V600E signaling may be a possible mechanism for the upregulation of Mps1 protein in human tumors, and that deregulation of Mps1 stability and kinase activity by BRAF V600E signaling contributes to centrosome re-duplication and chromosome segregation errors in human melanoma. Simultaneous inhibition of processes required for chromosome segregation may be an efficient way to kill tumor cells, especially when used in combination. 39 For an increased understanding of the role of this molecular linkage in tumorigenesis and the utility of such proteins as an anti-cancer strategy, development of small molecule inhibitors will be extremely valuable.
MATERIALS AND METHODS
Centrosome re-duplication assay and immunofluoresence
Immunofluoresence and centrosome re-duplication assay were performed as previously described. Additional experimental details are described in the Supplementary Information.
